Evidence map›Paper›PMID 37892594›Full record

ArticleJournal of clinical medicine2023

The Surreptitious Burden of Nonalcoholic Fatty Liver Disease in the Elderly in the Asia-Pacific Region: An Insight from the Global Burden of Disease Study 2019.

Pojsakorn Danpanichkul, Siwanart Kongarin, Sarunpakorn Permpatdechakul, Natchaya Polpichai, Kwanjit Duangsonk, Worapaka Manosroi, Nathorn Chaiyakunapruk, Omar Y Mousa, Donghee Kim, Vincent L Chen and 1 more

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 2 countries.

Pojsakorn DanpanichkulImmunology Unit, Department of Microbiology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.
Siwanart KongarinFaculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.
Sarunpakorn PermpatdechakulFaculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.ORCID 0009-0000-1543-0159
Natchaya PolpichaiDepartment of Internal Medicine, Weiss Memorial Hospital, Chicago, IL 60640, USA.
Kwanjit DuangsonkDepartment of Microbiology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.
Worapaka ManosroiDivision of Endocrinology, Department of Internal Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.ORCID 0000-0002-3007-3951
Nathorn ChaiyakunaprukDepartment of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT 84112, USA.ORCID 0000-0003-4572-8794
Omar Y MousaDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic, Rochester, Mayo Clinic Health System, Rochester, MN 55902, USA.
Donghee KimDivision of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0003-1919-6800
Vincent L ChenDivision of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 41809, USA.ORCID 0000-0002-0157-6066
Karn WijarnpreechaDivision of Gastroenterology and Hepatology, Department of Medicine, University of Arizona College of Medicine, Phoenix, AZ 85004, USA.ORCID 0000-0002-6232-6343
Chiang Mai University · THMayo Clinic Health System · USStanford University · USUniversity of Arizona · USUniversity of Michigan · USUniversity of Utah · USWeiss Memorial Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nonalcoholic fatty liver disease (NAFLD) represents a significant health threat worldwide. The aging population and a rise in metabolic syndrome in Asia might influence the epidemiology of NAFLD among the elderly. However, there is a lack of understanding of the burden and recommendations for NAFLD in this group. Our study sought to investigate the trends in the NAFLD burden among the elderly in the Asia-Pacific region. We employed data from the Global Burden of Disease 2019 study for an in-depth analysis of the prevalence and disability-adjusted life years (DALYs) along with age-standardized rate (ASR) associated with NAFLD in elderly populations (age 65-89 years) across the Asia-Pacific region, including the Southeast Asia (SEA) and Western Pacific (WP) regions, from 2010 to 2019. This study also examined the trends and disparities in NAFLD burden across different nations and sexes. In 2019, there were over 120 million cases of NAFLD in the elderly in the Asia-Pacific region. The ASR of prevalence was higher in SEA compared to WP (36,995.37 vs. 32,821.78 per 100,000). ASR of prevalence increased with annual percentage change (APC) +0.95% in the WP while it increased by +0.87% in SEA. During the study period, the ASR of DALYs decreased in SEA (APC -0.41%) but remained stable in the WP region. The burden of NAFLD in the elderly population in Asia-Pacific has increased, underscoring the timely intervention to tackle this high and rising burden.

Indexed as

Asiaelderlyepidemiologygeriatricssteatotic liver disease

Identifiers

PMID37892594
PMCPMC10607093
OpenAlexW4387540516

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.